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An association between hepatitis C virus infection and neuropsychiatric symptoms has been
proposed for some years. A variety of studies have been undertaken to assess the nature and
severity of these symptoms, which range from fatigue and depression to defects in attention
and verbal reasoning. There is evidence of mild neurocognitive impairment in some patients
with HCV infection, which is not fully attributable to liver dysfunction or psychosocial factors.
Further evidence of a biological cerebral effect has arisen from studies using magnetic resonance
spectroscopy; metabolic abnormalities correlate with cognitive dysfunction and resemble the
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Quasispeciespatterns of neuroinflammation that have been described in HIV infection. Recent research has
suggested that, in common with HIV infection, HCV may cross the blood brain barrier leading
to neuroinflammation. Brain microvascular endothelial cells, astrocytes and microglia may be
minor replication sites for HCV. Importantly, patient reported outcomes improve following
successful antiviral therapy. Further research is required to elucidate the molecular basis for
HCV entry and replication in the brain, and to clarify implications and recommendations for
treatment.
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Chronic hepatitis C virus (HCV) infection is important glob-
ally as a cause of liver-related morbidity and mortality with
hepatic fibrosis, cirrhosis and hepatocellular carcinoma as
the major clinical sequelae [1]. Hepatic encephalopathy as a
complication of HCV-induced cirrhosis and portal hyperten-
sion, is the most obvious manifestation of (CNS) involvement,
albeit indirect and non-specific [2]. CNS vasculitis can rarely
result from HCV-associated mixed cryoglobulinaemia [3],
which more commonly causes a peripheral sensory or motorneuropathy [4]. The suggestion that chronic HCV infection
itself might directly cause cerebral dysfunction came from ini-
tial, anecdotal observations that patients with HCV infection,
but without cirrhosis or cryoglobulinaemia, frequently
reported a range of non-specific symptoms [5]. For example,
fatigue is the commonest symptom in HCV infection, affecting
53% of patients in one large series [6]. HCV infected individu-
als with minimal liver disease have also shown increased levels
of depression and diminished abilities in the areas of concen-
tration, attention, verbal learning, working memory, executive
functions and psychomotor performance. A large number of
studies have documented the prevalence of such symptoms
and their impact on health related quality of life (HRQL) in
cohorts of patients with HCV infection [7–13]. This paper will
review the evidence for a link between HCV infection and CNS
symptoms.
Health-related quality of life
HRQL refers to an individual’s personal assessment or percep-
tion of his/her physical, mental and social well-being. Disease
specific and generic HRQL questionnaires have been employed
widely to study the impact of HCV infection on patients’ well-
being and the effects of anti-viral therapy. These data chal-
lenge the historical perception that HCV infection is an
‘‘asymptomatic” disease, with a consensus that HRQL is sig-
nificantly reduced in HCV infected patients [10,11,14]. Even
in patients without significant liver disease, HRQL is impaired
and is driven by fatigue, depression and cognitive impairment
[15,16]. One early study reported reduced Short-Form 36 (SF-
36) HRQL scores in patients with HCV infection compared to
patients with hepatitis B (HBV) infection. HRQL was more
impaired in HCV patients and this was unrelated to the mode
of acquisition (ie previous intravenous drug usage) [17]. These
findings and other cohort studies, outlined in this review sug-
gest a direct impact of HCV infection per se on HRQL. There
are however other important determinants related to physical
and psychiatric comorbidities, impact of a diagnosis and anx-
iety about prognosis, treatment and stigmatization [18–20].
Rodger and colleagues administered the SF-36 questionnaire
to a cohort of subjects who were admitted to hospital in the
1970s with acute hepatitis, a proportion of whom were una-
ware of their diagnosis of chronic HCV infection. Those who
were aware of their serostatus rated significantly worse on
seven of eight SF-36 scales compared to population norms,
whereas those who did not know their diagnosis scored signif-
icantly worse in only three scales [18]. The authors concluded
that reduced HRQL might result from labelling as a conse-
quence of the diagnosis. However, other prospective studies
of blood donors have revealed impaired SF-36 scores in
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sis, compared both to donors who tested HCV negative and to
those who had a false positive result [21,22]. The data together
suggest the presence of an independent effect of HCV infection
on HRQL, which may be compounded by the impact of diag-
nosis. There are clearly numerous factors that may explain
reduced HRQL in patients with HCV, ranging from physical
to psychosocial influences and the question of the presence
of a direct effect of HCV infection has become unnecessarily
dichotomized in this context [23]. What has emerged from
large studies in the era of directly acting antivirals is that there
is a rapid and clinically important improvement in well-being,
as viraemia is controlled [14,24]. Although previous interferon-
containing treatments also demonstrated positive HRQL
impacts over time [11], the improvements were delayed due
to the adverse effects on interferon and/or ribavirin. In an
analysis of 1952 patients treated in three major clinical inter-
feron free trials of sofosbuvir and ledipasvir ± ribavirin,
patient reported outcomes improved after just two weeks of
treatment with the ribavirin free combination and coincided
with viral suppression [24]. Improvements in at least ten
patient reported outcomes (including the SF-36 physical and
mental summary scales and the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F) measures)
exceeded the minimal clinically important difference in 37%
of patients by week four and by 47% at the end of treatment.
The study provides important evidence to support the hypoth-
esis that HCV itself is responsible for a major component of
HRQL impairments.
Fatigue
Fatigue is one of the most commonly reported symptoms of
infection with hepatitis C, and can be persistent and debilitat-
ing [6,19,25–29]. It has been assessed using various qualitative
and quantitative methodologies in the literature, with a
reported prevalence ranging from 20% to 80% in different
cohorts. Fatigue severity does not appear to correlate with
the degree of biochemical hepatitis [7,12,19]. Huckans reported
associations between neuropsychiatric symptoms including
fatigue and depression and the inflammatory profile of 47
immune factors measured in plasma using a multiplex
microbead methodology [30], suggesting that peripheral
immune activation may potentially contribute to this symp-
tom. However, fatigue is a multidimensional symptom and is
influenced by multiple, interrelating social, psychological and
physical factors [19,27,31], meaning that the relative contribu-
tion of a biological mechanism, if there is one, remains unclear.
As a consequence of any potential cerebral effect of HCV
infection, measured fatigue is unlikely to be a useful marker
in mechanistic studies. However, as a patient reported out-
come in clinical trials, marked improvements in treatment
responders suggest a viral contribution [24,32,33].
Depression
Depression is a common finding in HCV-infected patients
[19,20,34,35]. As well as being an important comorbidity,
depression has limited the tolerability of and compliance with
a-interferon based treatments [36]. The relationship between
HCV and depression is undoubtedly complex. The prevalenceof HCV in psychiatric populations is significantly increased
above the general population (17.4% in those with serious
mental illness in the USA [37], compared to a rate of around
1% in the general population), suggesting that those infected
with HCV are more likely to suffer from problems such as
depression in the first place. In Western Europe and the
USA, HCV infection occurs predominantly in current or for-
mer injection drug users, who have a higher prevalence of
depression [38]. Conversely, a reactive depression may relate
to the diagnosis of HCV infection and associated anxiety over
long term health or may it be secondary to symptoms such as
fatigue and cognitive impairment [27]. Finally, a biological
effect of HCV infection itself may underlie depression.
Although there is a large literature that describes the patho-
genesis of a-interferon induced depression [36], there is cur-
rently little evidence of an effect of endogenous cytokines.
Pawlowski and colleagues measured gene transcripts from
peripheral blood mononuclear cells of 28 cytokines and
chemokines in patients before and during a-interferon based
therapy [39]. Before treatment, neuroticism scores correlated
with IL-3, IL-8 and M-CSF transcription levels. Six months
after the end of therapy there was a correlation between
depression and/or neuroticism scores and various pro-
inflammatory cytokines. The authors concluded that there
might be a pivotal role for immune cell activation in depression
in chronic HCV infected patients.
Cognitive dysfunction
In 2001 cerebral magnetic resonance spectroscopy (MRS) was
used for the first time in HCV infected patients with minimal
liver fibrosis and demonstrated metabolic abnormalities in
white matter and basal ganglia, compared to both patients
with HBV infection and normal controls [40]. Subsequently
there followed a large number of studies to determine whether
there is evidence of neurocognitive impairment in HCV infec-
tion. The literature is heterogeneous and characterized by
cross-sectional rather than longitudinal assessments of rela-
tively small and selected cohorts. Potential confounding fac-
tors such as psychiatric disorders, injection drug use, recent
interferon treatment or liver cirrhosis were controlled for to
varying degrees. Furthermore, a variety of neuropsychological
test batteries have been employed to test different domains of
cognitive function, limiting the validity of comparisons
between studies.
In order to control for impairment due to the presence of
minimal hepatic encephalopathy (MHE), patients with cirrho-
sis should be excluded. The cognitive defects of MHE are well
delineated, and include reductions in selective attention, visuo-
constructive function and motor performance. Weissenborn
[41] tested a cohort of 30 patients with HCV without cirrhosis
and found that while levels of anxiety, depression, fatigue,
attention and executive function were affected, motor perfor-
mance and visuospatial function were relatively preserved, sug-
gesting an independent effect of HCV infection. Moreover,
these results were associated with MRS changes, which were
qualitatively different from those encountered in hepatic
encephalopathy.
Most studies have recruited patients from hospital clinic
settings with the concomitant risk of selection bias and the true
prevalence of cognitive impairment has not been defined.
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strated relatively mild impairments of attention, concentration
and working memory. For example, in one study of patients
with histologically mild liver disease, selective impairments of
concentration and working memory were reported that were
not seen to the same degree in patients, who had recovered
from HCV infection, either spontaneously or after successful
therapy. Furthermore, although patients with depression or
former substance abuse were not excluded from the study,
the presence of fatigue, depression or a history of substance
abuse did not explain these findings [35]. Hilsabeck and col-
leagues performed two studies in this field [25,42] and reported
that cognitive test performance was associated with fibrosis
stage on liver biopsy. However impairments in attention and
concentration were evident in HCV-patients with minor hep-
atic injury, affecting up to 50% of non-cirrhotic patients.
The pattern of impairment was similar to the findings
described by others and was thought to be consistent with
frontal-subcortical dysfunction, similar to the pattern encoun-
tered in HIV-infection. In their second study, there were no
associations between subjective complaints of cognitive dys-
function or fatigue and performance on the neuropsychologi-
cal tests. In contrast, Weissenborn and colleagues found that
distinct attention and higher executive deficits were more pro-
nounced in patients with moderate rather than mild fatigue
[41].
Some authors have attempted to control for confounding
factors through exclusion. Lowry and colleagues studied a
small, homogenous cohort of iatrogenically infected women,
of whom 9 had spontaneously cleared HCV, and showed that
PCR positive women had impaired memory and attention
compared to normal controls and the PCR negative group
[43]. McAndrews and colleagues applied strict exclusion crite-
ria to reduce confounding factors. Attention and speed of pro-
cessing were not impaired in this study, with only minimally
poorer learning efficiency in a small proportion (13%) of
HCV patients compared to controls [44]. Similarly, other stud-
ies have found no association between HCV infection and
impaired cognitive function, although these have involved
small groups of patients [42,45,46]. One such study recruited
participants who were screened for infection with HCV at
blood donation centres, thus removing several confounding
factors [45], with the caveat that this group may have been
self-selected for general good health and well-being. No cogni-
tive impairments were seen in viraemic patients, except in
patients with cirrhosis, which could potentially be explained
by MHE.
It is also important to note that, higher cognitive reserve as
evidenced by premorbid intellectual function and level of edu-
cation, may be protective against HCV-related cognitive
impairment [47,48]. One study divided patients into two
groups with ‘‘high‘‘ and ‘‘low” cognitive reserve. The results
differed between groups but were not shown to be statistically
significant [47]. The other study examined cirrhotic patients
and did not include controls [48]. Indeed, it is important to
match patients and controls for IQ, since cognitive impairment
in HCV infected patients is highly correlated with IQ and pre-
morbid cognitive ability [49].
Human immunodeficiency virus (HIV) infection can lead to
a range of neuropsychiatric manifestations, from asymp-
tomatic cognitive impairment to overt HIV-associated demen-
tia. Given that the patterns of impairment in some patientswith HCV infection are similar to HIV-associated mild neu-
rocognitive disorder, it has been postulated that there is an
underlying pathogenesis common to both diseases. Indeed,
patients co-infected with HIV and HCV are more likely to
have worse cognitive function than those with HIV mono-
infection [50], and this appears to be more than an additive
effect, raising the possibility that co-infection potentiates the
brain injury in these patients. Evidence for this comes from a
number of studies, including a cohort of drug users who were
classified based on serostatus for HIV and HCV [51]. Patients
with HIV/HCV co-infection performed worse on a voice-
activated reaction time version of the Stroop task, compared
to monoinfected subjects who had demonstrable impairments
compared to seronegative controls. The study did not control
for cirrhosis and it is possible that co-infected patients were
infected longer and had more severe liver disease. Studies from
the Manhattan HIV Brain Bank cohort [52] also showed worse
executive functioning in co-infection compared to individuals
with advanced HIV monoinfection. The authors concluded
that there was a detectable impact of HCV co-infection on
neurocognitive functioning, despite the advanced stage of
HIV disease of their cohort.
The literature clearly demonstrates evidence of neurocogni-
tive impairment in patients with chronic HCV infection. How-
ever, for the reasons outlined above, it is not clear that these
impairments can be attributed, wholly or in part, to the virus
itself. For this reason a number of brain imaging studies have
been reported, which have aimed to reveal a biological associ-
ation between HCV infection and cerebral effects.
Neuroimaging
Magnetic resonance spectroscopy (MRS) [35,40,41,44,53,54],
positron emission tomography (PET) [54,55] and single pho-
ton emission computed tomography (SPECT) [56] are imaging
techniques that have been used to determine whether biologi-
cal abnormalities are associated with the neuropsychological
impairment that has been observed in HCV infection. More
recently, MRI-perfusion weighted imaging and diffusion ten-
sor imaging have also been deployed to provide information
regarding cerebral blood flow and cellular microarchitecture
respectively [57–59].
MRS allows measurement of metabolite concentrations in
specific brain regions. Metabolite abnormalities have been
reported in a number of conditions such as multiple sclerosis,
brain tumours and HIV infection [60,61]. In HIV infection,
increased frontal white matter concentrations of myoinositol
(mI) and choline (Cho) are associated with increasing levels
of HIV-associated cognitive impairment [62], findings consis-
tent with CNS glial cell proliferation and cell membrane injury
respectively. Choline is an osmolyte that acts as a marker for
cell membrane synthesis and turnover [63]. In untreated
patients with HIV infection, reduced levels of frontal white
matter and basal ganglia N-acetyl aspartate (NAA), a marker
of neuronal integrity, and increased levels of mI have been
reported which reverse with anti-retroviral treatment [64]. This
methodology has been used to investigate whether similar
metabolite profiles are seen in HCV infection compared to
HIV infection where viral penetration into the CNS occurs.
Increases in Cho relative to creatine (Cr) in the basal
ganglia and frontal white matter have been reported in
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[40]. This was not associated with previous substance misuse
or seen in a control group of patients with chronic hepatitis
B infection. This is distinct from hepatic encephalopathy where
the Cho/Cr ratio is reduced [65], suggesting a different mecha-
nism underlies the findings in HCV infection. Only a weak
association between the abnormal metabolites and cognitive
performance was reported in this study. Using the same tech-
nique but different acquisition sequences, Weissenborn and
colleagues studied 30 HCV-infected patients with normal liver
function using careful cognitive testing and MRS [41]. They
reported reduced NAA/Cr ratios in occipital grey matter com-
pared to healthy subjects but no alterations of Cho containing
compounds or other abnormalities. Again there were no strong
associations between MRS metabolites and cognitive scores,
although in general, the deficits were more marked in moderate
rather than mild fatigue. McAndrews and colleagues under-
took MRS analysis on 37 HCV-infected patients with minimal
hepatitis, a group of patients who were highly selected to
exclude all possible relevant comorbidities and confounding
factors [44]. They demonstrated elevations in cerebral Cho
and reductions in NAA in voxels that were localized to the
central white matter. These findings are in keeping with both
the results from Weissenborn and Forton [35,40,41] and sug-
gest a decrease in neuronal activity and/or glial inflammation
and activation. In this study, there were only very mild cogni-
tive impairments confined to poorer learning efficiency in 13%
of subjects. More recently, Bladowska and colleagues reported
similar findings in a study of 15 HCV positive patients with no
neurological symptoms and normal plain MRI [57]. They
found that HCV infected individuals had reduced NAA/Cr
in frontal and parietal white matter.
Myoinositol (mI) is a cerebral osmolyte and a marker of
CNS inflammation and gliosis. Elevated white matter mI/Cr
ratios were reported that were significantly associated with def-
icits in working memory in a cohort of patients with mild liver
disease [53]. Elevations in white and grey matter mI have also
been described by Thames, who also demonstrated a positive
correlation between frontal white matter mI and both fatigue
and overall cognitive performance in a larger study of 76
patients with chronic HCV infection [59].
These findings contrast with the results reported by Boke-
meyer and colleagues [66]. Their study quantitatively assessed
metabolite levels in 53 HCV positive patients with mild liver
disease using MRS. There were increased levels of white matter
Cho and basal ganglia Cho and N-acetyl aspartate/N-acetyl-
aspartyl glutamate (NN). Although mI concentrations were
not increased in HCV patients, in contrast to Thames, they
correlated negatively with fatigue scores. Similar patterns were
seen for the other metabolites i.e. a negative correlation with
fatigue. The reason for this is not fully understood but NAA
is thought to demonstrate the number and function of neurons
and to be coupled to glucose/glycogen metabolism. MRS stud-
ies of other cerebral pathologies have shown raised NAA in
instances of neurocompensation. The authors concluded that
this study may provide evidence for neurocompensatory mech-
anisms in HCV infected patients that underlie the variation in
neurocognitive effects.
Studies have been limited by a number of factors including
differences in MR parameters for data acquisition, data anal-
ysis techniques, and inconsistent methods of neuropsychologi-
cal assessment. One can conclude however that definableMRS-measurable metabolic abnormalities exist in a propor-
tion of HCV-infected patients with minimal or absent liver dis-
ease, who have demonstrated fatigue and cognitive impairment
on formalized testing. Similar MRS findings are reported in
HIV-related minor-cognitive disorder and are considered to
represent neuronal dysfunction and immune activation of
microglial cells. It is therefore possible that neuroinflammation
may also occur in chronic HCV-infection.
More recent studies have used perfusion weighted imaging
(PWI) techniques to assess blood flow, and diffusion tensor
imaging (DTI) to interrogate cell microarchitecture in HCV
patients. Cerebral blood flow has been shown to be increased
in the basal ganglia and decreased in the cortices, showing cor-
relations with metabolite findings [57,58]. Hyperperfusion in
the basal ganglia may be an indicator of HCV associated neu-
roinflammation. DTI techniques used in two studies elicited
differing results. Thames et al. found increased fractional ani-
sotropy in the striatum and greater mean diffusivity in the
fronto-occipital fasciculus and external capsule compared to
controls [59]; this diffusivity in the fronto-occipital cortex
was positively correlated with fatigue scores, which were also
associated with increased white matter mI. The anatomical dis-
tribution suggested that HCV-associated neurological compli-
cations disrupted frontostriatal structures, which may result in
fatigue and impaired performance of cognitive tasks that
involve frontostriatal systems. Bladowska et al. however found
increased diffusivity in certain white matter tracts but
decreased fractional anisotropy. The significance of this is
not yet clear [57,59].
Further evidence for neuroinflammation in HCV is pro-
vided by PET studies that used a ligand (PK11195) that binds
to the peripheral benzodiazepine receptor, now termed translo-
cator protein, which is mainly expressed on the outer mito-
chondrial membrane of activated microglia. Increased ligand
binding in the caudate nucleus of HCV-infected patients was
reported by Taylor-Robinson’s group in a pilot PET study
of patients with histologically mild liver disease. These find-
ings, which correlated with viraemia, suggest the presence of
neuroinflammation [55]. Using the same PET ligand, Pflugrad
and colleagues studied the associations between cognitive
impairment, fatigue and viraemia in HCV-exposed patients
[67]. Patients reported greater fatigue and depression than
healthy controls and performed worse in some cognitive
domains including working memory and attention. However,
in this study no differences were seen between HCV poly-
merase chain reaction (PCR) positive (+ve) and negative
(ve) patients on any scales or cognitive tests. Increased
PK11195 binding was seen in PCRve patients in the frontal
cortex, compared to both controls and PCR+ve patients. Fur-
thermore, PK11195 binding in the basal ganglia and temporal
cortex was inversely associated with performance in atten-
tional tasks i.e. greater binding was seen in the least impaired
patients. The authors suggested that microglial activation
might be associated with neurogenesis and neuronal regenera-
tion that, in some way, provides a neurocompensatory effect,
thus explaining the negative correlation. However, the absence
of any association with HCV PCR status is perplexing. One
explanation might be that HCV exposure is sufficient to cause
a CNS effect without detectable ongoing viral replication.
Another might be that the findings in this study are unrelated
to HCV exposure, the attention and PET abnormalities and
relationships being due to another factor.
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HCV infection on neurotransmission [54] using single photon
emission computerized tomography in 20 patients with mini-
mal liver disease and fatigue. Pathological dopamine and sero-
tonin transporter binding was seen in 50–60% of patients,
which was associated with worse cognitive performance com-
pared to controls. The investigators have studied a further
cohort of 15 patients without cirrhosis but with longstanding
HCV exposure secondary to anti D immunoglobulin adminis-
tration 28 years previously [54]. Again, there was reduced stri-
atal dopamine and midbrain serotonin transporter availability,
which correlated with psychometric results and significantly
reduced glucose metabolism, measured with (18)F-fluoro-
deoxy-glucose PET, in the limbic association cortex, and in
the frontal, parietal, and superior temporal cortices. This study
is notable in that there were no significant differences in find-
ings between those who were PCR+ve and the four patients
who were PCRve. Patients were selected for demonstrating
symptoms associated with ‘‘HCV encephalopathy”. Although
numbers were small, the study raises the intriguing possibility
that CNS abnormalities may persist once virus is no longer
detectable in blood. The replication of the earlier SPECT data,
together with the association between striatal dopamine trans-
porter binding and regional cerebral hypometabolism, suggests
that cerebral dysfunction in HCV may be associated with alter-
ations in dopaminergic neurotransmission. In particular,
impaired mesotelencephalic dopamine projections to the fron-
tal lobe may underlie abnormalities in executive function and
working memory.
The neuroimaging studies share a number of limitations
including small study sizes, heterogeneity and varying selection
of patients, different neuropsychological assessment methods
and varying degrees of control matching. However, there is
convergent evidence to suggest the occurrence of neuroinflam-
mation, hypometabolism and dopaminergic signalling abnor-
malities in the brains of some patients with HCV infection.
The findings suggestive of neurocompensatory effects are in
keeping with this and are likely to be an area of continuing
research over the coming years.
Evidence for HCV infection of the CNS
HCV RNA has been detected in post-mortem brain samples
and cerebrospinal fluid (CSF) using PCR based methods, but
this alone does not prove productive infection or replication
because of the possibility of brain-blood barrier breakdown
after death [68–71]. However, low level HCV replication in
the CNS is suggested by more sophisticated molecular tech-
niques, including the detection of the negative strand of
HCV RNA, which is considered a replicative intermediate
[69] and distinct viral quasispecies within the brain samples
[69–71]. HCV RNA is detected at a 1000–10,000 fold lower
level in brain compared to liver, indicating that the brain is a
minor replication site at most [70]. Unique sequences incorpo-
rating the HCV internal ribosomal entry site (IRES) were
detected in the CNS [71]. The IRES mediates viral protein
translation and when theses variants were incorporated into
a reporter vector, there was a reduction in translational effi-
ciency, which may represent a possible mechanism for CNS
latency [71]. More recently, a deep sequencing approach hasdemonstrated genetic compartmentalization of HCV within
the CSF, obtained from cognitively impaired patients with
HCV infection [72]. Although the number of subjects was nec-
essarily small, independent viral evolution of HCV envelope
sequences was seen in the CSF of two cognitively impaired
patients but was not observed in cognitively preserved patients,
consistent with viral sequestration.
Immunohistochemical and molecular techniques have
indicated that microglia and astrocytes are cellular targets
for HCV infection [73,74]. Wilkinson and colleagues showed
that cells that stained for HCV non-structural protein 3
(NS3), costained for CD68, a microglial marker. When these
cells were isolated by microdissection and pooled RNA was
amplified, there was expression of microglial markers and
also of increased proinflammatory genes such as TNF-a
and IL-12 [74]. Microdissected cells from HCV+ patients
that were negative for NS3 did not express proinflammatory
genes. These studies, which include HCV mono- and
co-infected patients, are consistent with microglial immune
activation, as a consequence of HCV infection and parallel
the findings from the clinical PET studies using PK 11195
[55,67].
HCV core protein has been shown to trigger activation of
the extracellular signal-related kinase (ERK)/signal transducer
and activator of transcription 3 (STAT3) system via toll-like
receptor 2 (TLR2) in the CNS [75]. Analysis of post mortem
brain tissue, revealed increased phospho-ERK levels in HCV
infected patients that was not seen in patients with HIV
encephalitis or in HCV seronegative patients [75]. Using a neu-
ronal cell line, HCV core protein was shown to activate ERK
via TLR2 expression, which is thought to play a role in neu-
rodegeneration. This group also investigated the direct effect
of HCV core by introducing it to murine hippocampi. They
demonstrated ERK activation, dendritic shortening, reduced
neuronal density, astrogliosis and cytoskeletal disruption
[75]. These findings are in concordance with those from neu-
roimaging studies of metabolite changes and microarchitec-
tural breakdown.
The mechanism of HCV entry into the CNS has been pos-
tulated to be through infected monocytes, trafficking across
the blood-brain barrier [5]. Astroglia cell lines do not express
all the cell molecules required for classical HCV entry (tetra-
spanin, CD81 and tight junction proteins claudin-1 and occlu-
din) [76] and attention has turned to the blood/brain barrier.
Fletcher and colleagues have shown that brain microvascular
endothelial cells (BMECs), are permissive to HCV infection
in culture [77]. In a series of experiments, they demonstrated
infection of BMECs by culture-derived HCV and release of
particles that were subsequently infectious in Huh-7 hepatoma
cells, this being the first demonstration of HCV replication in
non-hepatocyte cell culture. Infected BMECs displayed apop-
tosis, which might result in reduced endothelial barrier activ-
ity. In this way, peripherally derived cytokines, viruses and
immune cells might gain access to the CNS across an HCV-
disrupted blood/brain barrier, resulting in immune activation
within the CNS. In addition viral proteins might act directly
to potentiate neurotoxicity, as suggested for HCV core protein
by Paulino [75] and in a report where HCV core protein poten-
tiated HIV-1 neurotoxicity in a mouse model [78]. It might
therefore be expected that CNS symptoms correlate with levels
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mixed results [30,72,79].
Changes following successful antiviral therapy for HCV
infection
Improvements in HRQL and reductions in fatigue levels occur
in patients with a sustained virological response (SVR) after
treatment with pegylated interferon and ribavirin [11]. The
use of these drugs is itself associated with physical, mental
and cognitive symptoms. The advent of the directly acting
antiviral (DAA) drugs, which have minimal side effects, pro-
vides an opportunity to study the impact of viral eradication
on HRQL. In a double blind placebo controlled randomized
clinical trial of Sofosbuvir/Velpatasvir in 750 patients with
hepatitis C, subjects completed questionnaires that assessed
25 patients reported outcomes (PROs) at baseline and every
four weeks through treatment [80]. Those who achieved a sus-
tained virological response were followed to 24 weeks after the
end of treatment. By week four of treatment, statistically sig-
nificant improvements were seen in general health, emotional
well-being, and fatigue in patients on treatment compared to
baseline in the patients on active treatment. These changes
were not seen in the placebo group. By the end of treatment
the improvement in PRO scores had continued with no
improvement in the placebo group. The patients were unaware
of their viral status when completing the assessments. A mul-
tivariable analysis was performed, which took into account
baseline levels of the PROs in addition to clinical and demo-
graphic factors, and demonstrated that treatment emergent
changes in the PROs, including fatigue, during and after treat-
ment were independently predicted by receiving antiviral treat-
ment as opposed to placebo. The data definitively show that
viral suppression per se improves patient symptoms including
fatigue, depression and anxiety. Similar results have been
reported for other compounds [81].
The impact of successful HCV clearance on cognitive func-
tion and brain metabolism has also been studied. In a trial of
168 patients, Kraus and co-workers showed that successful
HCV eradication with peginterferon and ribavirin was associ-
ated with improved attention, vigilance, and working memory,
while virological non-responders showed no such improve-
ments [82]. These improvements in cognitive function were
demonstrated one year after the end of treatment to control
for the known effect of interferon-based treatment on brain
function during the treatment period. A much smaller pilot
study [83] using brain proton MRS and cognitive assessments
before, during and after interferon-based therapy, showed sig-
nificant CNS metabolic changes towards normal levels in those
patients who had an SVR. These findings were interpreted as
improvement in cerebral immune activation associated with
HCV clearance, although any conclusion is limited by the very
small study groups. No convincing changes were seen in cogni-
tive performance. More recently, a similar MRS study using
interferon free treatment with Sofosbuvir and Ledipasvir,
reported normalization of cerebral N-acetyl aspartate, in
patients with viral suppression, which was interpreted as recov-
ery of neuronal dysfunction [84]. These studies were small and
need to be validated in a larger sample of patients undergoing
treatment with DAA drugs to understand the relationship
between viral eradication, cognitive function and brain imaging.Conclusions
The clinical evidence for neuropsychological impairment in
HCV infection has aroused interest but the clinical significance
in terms of disease endpoints remains to be defined. For exam-
ple, an association between HCV infection and Parkinson’s
disease has been reported in a very large epidemiological study
in Taiwan [85]. Much of the evidence to date has been drawn
from small, variably controlled studies, on a background of
multiple confounding factors. HCV therapy has advanced
rapidly, with the availability of highly effective, directly acting
antiviral drugs without major side effects. Large prospective
studies are required to determine whether these new treatment
regimens reverse neurocognitive symptoms and brain abnor-
malities in HCV-infection. This will be the true test of whether
there is a direct biological effect of this virus on the CNS.
Finally, the presence of an immune privileged, extrahepatic site
could be a potential source of late relapse after oral antiviral
therapy and long-term surveillance is advised.
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